SCHEMBL10276957

SCHEMBL10276957

Cc1ccc(-c2cn3nc(N4CCS(=O)(=O)CC4)ccc3n2)cc1NC(=O)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 4/20 0.37
CSNK1E P49674 4/20 0.37
RXFP1 Q9HBX9 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 1/20 0.37
KMT2A Q03164 1/20 0.36
MAPT P10636 3/20 0.36
TP53 P04637 3/20 0.35
LMNA P02545 1/20 0.35
RIPK1 Q13546 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
PIM1 P11309 1/20 0.34
KDR P35968 1/20 0.33
WDR5 P61964 1/20 0.33
POLB P06746 1/20 0.33
RAF1 P04049 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10276959 0.93 CSNK1D (0.37) CSNK1DCSNK1ERXFP1NPC1RAB9A
SCHEMBL10277613 0.89 RXFP1 (0.39) CSNK1DCSNK1ERXFP1NPC1RAB9A
SCHEMBL9956948 0.88 PTGER4 (0.40) CSNK1DCSNK1ERXFP1NPC1RAB9A
SCHEMBL9956145 0.88 RBP4 (0.41) CSNK1DCSNK1ENPC1RAB9AKDM4E
SCHEMBL9956014 0.87 PTGER4 (0.41) CSNK1DCSNK1ERXFP1NPC1RAB9A
SCHEMBL9956518 0.85 MAPT (0.39) CSNK1DCSNK1ERXFP1NPC1RAB9A
SCHEMBL9956510 0.84 MAPT (0.37) CSNK1DCSNK1ERXFP1NPC1RAB9A
SCHEMBL9955725 0.84 RIPK1 (0.39) CSNK1DCSNK1ERXFP1MAPTTP53
SCHEMBL9955779 0.84 RIPK1 (0.38) CSNK1DCSNK1ERXFP1NPC1RAB9A
SCHEMBL9955783 0.84 RIPK1 (0.38) CSNK1DCSNK1ERXFP1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178751-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES HENGRUI (USA), LTD. 2012-07-12 US claimed
EP-2635578-B1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES HENGRUI USA LTD (US) 2015-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178751-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES PRXL2A, CDK2, CCNA2 CSNK1D 655/4885CSNK1E 852/4885RXFP1 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.